设计,合成和评价基于eugenol的纤维酸衍生物作为新型降脂剂
Boling Zhou1, Kexin Xu1, Wenjing Li1
1College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave., Xi'an-xianyang New Ecomic-Zone, Shaanxi Province 712046, People's Republic of China.
Bioorganic chemistry
|October 29, 2025
概括
新的尤根醇纤维酸化合物被合成用于治疗高甘油三血症. 衍生品T7显示出显著的降脂效应,并通过作为PPAR-α激动剂来改善肝脏安全性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 长期使用纤维化药物治疗高甘油三血症可能会导致肝毒性.
- 开发更安全的降脂剂至关重要.
研究的目的:
- 设计和合成新型欧原醇纤维酸衍生物,以改善脂质特征.
- 评估这些新化合物的疗效和肝安全性.
- 研究其作用机制,重点关注PPAR-α激动作用.
主要方法:
- 分子杂交和生物异构主义被用于化合物设计.
- 在急性和慢性高脂血症模型中评估了降脂潜力.
- 用分子对接和西方污点分析来研究该机制.
- 评估了肝毒性标志物 (AST,ALT),炎症和脂质积累.
主要成果:
- 乙烯6-6-(4--2-甲基氧) 六酸 (T7) 呈现出最佳的,剂量依赖的降脂活性.
- T7通过强烈的结合亲和力和标蛋白上调来表现出强大的PPAR-α激素作用.
- T7显著降低了肝酶 (AST,ALT),肝炎和脂质积累.
- 该化合物显示出抗炎和抗氧化特性,改善肝脏安全性.
结论:
- 用纤维酸混合欧原醇为降脂药物开发提供了一种新的策略.
- 尤根醇纤维酸衍生物,特别是T7,有望提高疗效和降低肝毒性.
- 这种方法可能会导致更安全,更有效的治疗过高甘油三血症.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Lipid-derived Compounds in the Human Body
6.2K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
6.2K
Lipid Digestion
98.6K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
98.6K
Bioavailability Enhancement: Drug Permeability Enhancement
183
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
183
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Biosynthesis of Lipids
519
Microbial membranes exhibit remarkable diversity in lipid composition, reflecting evolutionary adaptations to various environmental conditions. The three domains of life—Bacteria, Archaea, and Eukarya—synthesize membrane lipids through distinct biosynthetic pathways, leading to fundamental structural differences that impact membrane stability, function, and adaptability.Fatty Acid-Based Lipids in Bacteria and EukaryaBacteria and eukaryotes share a common fatty acid biosynthesis...
519


